University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Masters Theses

Graduate School

12-2020

Roles of Select Cytochrome P450 Epoxygenases in Brown
Adipogenesis
Katherine Marie Graham
University of Tennessee, Knoxville, kgraha19@vols.utk.edu

Follow this and additional works at: https://trace.tennessee.edu/utk_gradthes
Part of the Molecular, Genetic, and Biochemical Nutrition Commons

Recommended Citation
Graham, Katherine Marie, "Roles of Select Cytochrome P450 Epoxygenases in Brown Adipogenesis. "
Master's Thesis, University of Tennessee, 2020.
https://trace.tennessee.edu/utk_gradthes/5838

This Thesis is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and
Creative Exchange. It has been accepted for inclusion in Masters Theses by an authorized administrator of TRACE:
Tennessee Research and Creative Exchange. For more information, please contact trace@utk.edu.

To the Graduate Council:
I am submitting herewith a thesis written by Katherine Marie Graham entitled "Roles of Select
Cytochrome P450 Epoxygenases in Brown Adipogenesis." I have examined the final electronic
copy of this thesis for form and content and recommend that it be accepted in partial fulfillment
of the requirements for the degree of Master of Science, with a major in Nutrition.
Ling Zhao, Major Professor
We have read this thesis and recommend its acceptance:
Ling Zhao, Ahmed Bettaieb, Guoxun Chen
Accepted for the Council:
Dixie L. Thompson
Vice Provost and Dean of the Graduate School
(Original signatures are on file with official student records.)

Roles of Select Cytochrome P450 Epoxygenases in
Brown Adipogenesis

A Thesis Presented for the
Master of Science
Degree
The University of Tennessee, Knoxville

Katherine Marie Graham
December 2020

Copyright © 2020 by Katherine Marie Graham
All rights reserved.

ii

ACKNOWLEDGEMENTS
I would like to thank my advisor, Dr. Ling Zhao, and my committee members, Dr. Guoxun Chen
and Dr. Ahmed Bettaieb, for offering their expertise, guidance, and training throughout my
graduate coursework and research. Thank you to my fellow lab members, Yang Yang, Xinyun
Xu, Sue Choi, Kelsey Hildreth, Myah Trevethan, Haley Overby, and Emily Hager for their
support and assistance. Finally, I would like to thank my wonderful parents and boyfriend, Jack,
for their continuous love and encouragement throughout graduate school.

iii

ABSTRACT
Brown adipose tissue (BAT) has recently emerged as a novel target for obesity treatment
and prevention. Cytochrome P450 (CYP) epoxygenases, primarily CYP2J and CYP2C isoforms,
produce epoxy fatty acids (EpFAs), which have been suggested to play important roles in the
regulation of white adipogenesis and obesity. However, adipocyte-specific expression of CYP
epoxygenases has not been extensively analyzed, and the roles of CYP epoxygenases in brown
adipogenesis remain unexplored. In this study, we examined mRNA levels of Cyp2j and Cyp2c
isoforms during murine and human brown and white adipocyte differentiation and in various
adipose tissue depots of high-fat diet (HFD)-fed and control mice. Moreover, we began to
elucidate the roles of select CYP epoxygenases in brown adipogenesis through modulation of
CYP expression. Stable transfection and lentiviral-mediated knockdown of murine Cyp2j13 and
stable transfection of human CYP2J2 were performed in brown preadipocytes and their
differentiation potentials were compared with cells that were transfected with empty vector or
non-targeting knockdown controls. The effects on brown adipogenesis were evaluated by lipid
accumulation and expression of brown adipocyte and general differentiation marker genes. We
report that mRNA levels of CYP epoxygenases are increased in mature adipocytes compared to
preadipocytes but decreased in the most strongly differentiated murine brown adipocytes.
Furthermore, Cyp2j mRNA levels displayed an upward trend in the BAT of HFD-fed mice,
implicating that Cyp2j expression may be associated with reduced BAT mass and activity. We
show that Cyp2j13 overexpression significantly suppressed murine brown adipocyte
differentiation, while Cyp2j13 knockdown enhanced differentiation, suggesting that Cyp2j13
may be a negative regulator of brown adipogenesis. In contrast, CYP2J2 overexpression did not
remarkably affect human brown adipocyte differentiation. Together, our results suggest that CYP
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epoxygenases may play important roles in brown adipogenesis. Cyp2j13, in particular, may be a
novel target for brown adipogenesis, and consequently, for obesity treatment and prevention.
Further studies are warranted to examine the roles of CYP2J2 by gene knockdown and
pharmacological antagonism, to determine whether CYP2J2 overexpression may alleviate
inflammation-induced suppression of brown adipocyte differentiation and activity, and to
analyze roles of other CYP epoxygenase isoforms in brown adipogenesis for obesity treatment
and prevention.
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CHAPTER I
INTRODUCTION
The worldwide prevalence of obesity has nearly tripled from 1975 to 2016. In 2016,
nearly 1.9 billion adults were overweight, and 650 million of these adults were obese [1]. As
global rates of obesity continue to rise, it is of increasing importance to develop novel
therapeutic strategies to combat this pandemic along with its accompanying comorbidities such
as type 2 diabetes and cardiovascular disease. Obesity is fundamentally characterized by a
chronic energy imbalance, in which energy storage exceeds energy expenditure [2]. White
adipose tissue (WAT) is the principal site of energy storage in the body, accumulating excess
energy in the form of lipid droplets [3, 4]. In contrast, brown adipose tissue (BAT) is a site of
energy expenditure due to its thermogenic potential [5, 6]. Metabolically active BAT was
previously thought to only exist in human infants, as a method of adaptation to cooler extrauterine temperatures following birth [5, 6]. More recently, significant amounts of functional
BAT were found to be present in adult humans [7, 8]. This discovery has introduced a realm of
research investigating strategies to manipulate the thermogenic capacity of BAT as a means of
enhancing energy expenditure, thus aiding in reversal of the chronic energy imbalance that
underlies obesity.
Polyunsaturated fatty acids (PUFAs) are fatty acids that are metabolized into a variety of
signaling molecules known as eicosanoids, which are key mediators of inflammation [9]. The
cytochrome P450 (CYP) epoxygenase pathway of PUFA metabolism produces epoxy fatty acids
(EpFAs) such as arachidonic acid (ARA)-derived epoxyeicosatrienoic acids (EETs), which exert
anti-inflammatory, anti-oxidative stress, vasodilatory, and angiogenic actions by activating
receptor-mediated signaling pathways and ion channels [10]. EETs and other EpFAs have been
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demonstrated to produce favorable effects on obesity and its related metabolic diseases such as
attenuation of high-fat diet (HFD)-induced increases in body weight, adiposity, serum lipids,
insulin resistance, and vascular dysfunction, in numerous studies [10-13]. These metabolic
effects are partially mediated through adipocyte-specific actions, as increasing EET
concentrations in white preadipocytes has been shown to decrease their ability to differentiate
and accumulate lipids [14]. CYP epoxygenase overexpression is one method of increasing EpFA
production to elicit these positive outcomes [15]. However, the specific CYP isoforms expressed
in adipocytes that contribute to EpFA production are not well characterized. Additionally, the
role of CYP epoxygenases and subsequent EpFA production remains unexplored in brown
adipocytes, and it is unclear if the observed metabolic benefits can be partially attributed to an
increase in BAT development and activation. In the current study, we sought to determine which
CYP epoxygenase isoforms are expressed in brown and white adipocytes throughout
differentiation and in diet-induced obesity. Furthermore, we began to elucidate the role of CYP
epoxygenases in brown adipogenesis through modulation of CYP expression in brown adipocyte
differentiation. The results presented contribute to our understanding of adipocyte CYP
epoxygenase expression and suggest a role of these enzymes in brown adipocyte differentiation.
Together, this provides promising areas for future research to uncover methods to manipulate the
CYP pathway to ameliorate the debilitating consequences of obesity in our world.
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CHAPTER II
LITERATURE REVIEW
2.1. Adipose Tissue and Metabolic Homeostasis
2.1.1. Types of Adipose Tissue
Three major types of adipose tissue are recognized to exist in mammals, each of which
plays different roles in metabolic homeostasis and obesity development. White adipose tissue
(WAT) is distributed throughout the body, with its primary function being the storage of energy
as triacylglycerols (TAG) and the release of this energy through lipolysis to free fatty acids
(FFAs) and glycerol. WAT is considered an endocrine organ and regulates a variety of
physiological processes through the synthesis and secretion of biologically active compounds,
such as hormones and cytokines, which are deemed as adipokines [3, 4]. In circumstances of
energy surplus, WAT possesses the ability to expand and proliferate through hypertrophy and
hyperplasia in order to accommodate excess lipids. Excessive lipid accumulation is characteristic
of obesity and prompts a state of chronic inflammation and oxidative stress in WAT, leading to a
dysregulated gene expression profile and altered adipokine production, and ultimately driving the
metabolic diseases associated with obesity [3, 4].
Brown adipose tissue (BAT) exists in discrete depots throughout the body and is
histologically and functionally distinct from WAT. While white adipocytes are large in size with
a unilocular lipid compartment, brown adipocytes are smaller with numerous lipid droplets [6,
16, 17]. Most notably, brown adipocytes are far more concentrated in mitochondria, which gives
the tissue its darker color and renders it more metabolically active. BAT possesses a unique
protein on the inner membrane of its mitochondria known as uncoupling protein-1 (UCP1),
which facilitates its ability to undergo non-shivering thermogenesis, a process of heat production.
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In the electron transport chain, UCP1 uncouples the proton motive force from adenosine
triphosphate (ATP) synthesis by allowing H+ to leak into the mitochondrial matrix, thus
dissipating this energy as heat and elevating overall energy expenditure. BAT is highly
vascularized to allow for delivery of substrates and oxygen to facilitate this heat production and
in order to effectively transmit generated heat to other tissues in the body [5, 6, 16, 17].
A third form of adipose tissue has also been described, in which adipocytes located
within WAT can be recruited in response to various stimuli to express a BAT-like phenotype,
with multilocular lipid droplets, increased mitochondria, and UCP1 expression, allowing these
cells to facilitate thermogenesis much like classical brown adipocytes. These inducible brown
adipocytes are referred to as beige adipocytes, and this process is known as the “browning” of
WAT [18-20]. Despite similarities in thermogenic function, brown and beige adipocytes should
be distinguished as different cell types due to numerous key discrepancies. Beige fat possesses a
distinct gene expression pattern compared to classical BAT. In contrast with classical BAT,
which elicits high basal UCP1 expression, expression of UCP1 in beige adipocytes is only
present upon stimulation [18-20]. Additionally, a number of quantitative trait loci are associated
with the induction of beige but not brown adipocyte development, signifying these cell types are
likely differentially regulated [21]. The extent to which these beige fat cells comprise the
functional BAT observed in adult humans is unknown [20], but nonetheless, both beige and
brown adipocytes display exciting potential for therapeutic outcomes in obesity due to their
energy expending capacity.
2.1.2. Therapeutic Potential of Brown Adipose Tissue
The ever-increasing global burden of obesity and scarcity of effective treatments has
instigated a search for novel therapeutic targets. Due to its energy expending capacity, BAT
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holds great promise in this realm. BAT is inversely associated with body mass index, adiposity,
and type 2 diabetes incidence [22], suggesting that increasing BAT mass and activity can
ameliorate these conditions. It is estimated that approximately 50 grams of active BAT in
humans could account for a 20% increase in daily energy expenditure [23], which corroborates
the clinical relevance of enhancing BAT mass in obese individuals. BAT activity also decreases
with age, with an estimated 50% activity in individuals in their 20s compared to approximately
10% activity in those in their 50s and 60s [24]. This observation coincides with the known
decrease in basal metabolic rate with advancing age, indicating potential for a more remarkable
metabolic impact with enhanced activation in an older population [25].
In addition to associational evidence in humans, BAT-mediated thermogenesis has
demonstrated to directly impact body weight homeostasis in mouse models, with UCP1 ablation
inducing obesity and its associated complications in mice when housed at thermoneutral
conditions [26, 27]. Conversely, these mice did not become obese when housed at room
temperature [28]. BAT elicits additional functions that may act alongside body weight reduction
as a means to improve overall metabolic health. Namely, its ability to rapidly uptake and dispose
of circulating lipids and glucose may attenuate insulin resistance and hyperlipidemia, both of
which are commonly present in obese individuals [29, 30]. Together, this provides compelling
evidence that research examining factors to promote BAT development and activation is
warranted for its therapeutic potential in obesity.
2.1.3. Brown Adipose Tissue Development and Activation
Brown adipocytes, in addition to skeletal muscle cells and certain populations of white
adipocytes, are derived from Myf-5-expressing myogenic precursors [6, 31]. Once mesenchymal
stem cells (MSCs) are determined as preadipocytes, differentiation occurs to allow for
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development of the morphological and functional characteristics of mature adipocytes. This
adipocyte development process, including determination of stem cell fate and differentiation into
mature adipocytes, is referred to as adipogenesis [32]. Although there are numerous transcription
factors and other regulatory factors involved in the complex process of brown adipogenesis,
peroxisome proliferator-activated receptor gamma (PPARg), PR domain containing protein 16
(PRDM16), and PPAR gamma coactivator-1 alpha (PGC-1a) represent the key players involved.
PPARg is a ligand-activated nuclear receptor which dimerizes with retinoid X receptor (RXR)
and binds to peroxisome proliferator response elements (PPREs) to regulate expression of target
genes [33]. PPARg is primarily expressed in adipose tissue and is considered the master regulator
of adipogenesis, but also plays an integral role in the regulation of lipid metabolism, insulin
signaling, and adipokine production, among other functions [33]. PPARa, another PPAR
isoform, is more highly expressed in BAT rather than WAT and is predominantly involved in
lipid metabolism. PPARa can also induce adipogenesis, although not to the same extent as
PPARg [34].
As the master regulator of adipogenesis, PPARg is essential for the development of both
brown and white adipocytes [35, 36]; however, this transcription factor alone is not sufficient to
commit MSCs to a brown adipocyte lineage. Together with early B-cell factor 2 (EBF2),
PPARg stimulates expression of PRDM16 [21]. PRDM16 operates as a molecular bidirectional
switch to determine whether MSCs become myocytes or brown adipocytes [37]. Knockdown of
PRDM16 in brown adipocytes results in a loss of thermogenic potential and differentiation of
these cells into myocytes, whereas ectopic expression of this protein induces a thermogenic
phenotype in myoblasts [37, 38]. PRDM16 binds to and modulates the activity of a number of
transcription factors in brown preadipocytes that are imperative for differentiation and
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stimulation of thermogenic activity, including PPARg and PGC-1a [6, 39]. PGC-1a is
recognized as the chief controller of mitochondrial biogenesis and respiration and activates
thermogenesis in BAT through stimulation of UCP1 expression [39, 40]. Although PGC-1a is
essential for activation of thermogenic function in BAT, it is not believed to be involved in the
commitment to the BAT lineage from Myf-5-expressing precursors, as BAT develops normally
in PGC-1a-null mice [41].
In addition to knowledge regarding molecular mechanisms of BAT development,
comprehension of means to enhance BAT thermogenic activity is critical in order to unlock its
therapeutic potential. BAT is highly innervated with sympathetic nervous fibers, and activation
of the sympathetic nervous system (SNS) is recognized as a principal mechanism of BAT
thermogenesis induction [5, 6]. Upon SNS activation, norepinephrine is released and binds to b3adrenergic receptors on the cell surface of brown adipocytes, which triggers an intracellular
cascade resulting in the formation of cyclic adenosine monophosphate (cAMP) and subsequent
activation of protein kinase A (PKA). PKA phosphorylates and activates hormone sensitive
lipase (HSL), which initiates lipolysis, cleaving TAGs to FFAs and glycerol. These FFAs are
shuttled to BAT mitochondria, where they can induce UCP1 activity and thermogenesis [17].
Aside from adrenergic stimulation, numerous other factors have been described to activate
thermogenesis through interaction with various cell membrane and nuclear receptors in BAT,
including thyroid hormones, irisin secreted from skeletal muscle, and natriuretic peptides
released from the heart [21, 42].
Cold exposure results in norepinephrine release and serves as the most well-established
trigger for BAT thermogenesis, as a means to maintain body temperature [5]. Cold exposure not
only promotes activation of classical BAT but is also known to stimulate formation of beige fat
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to aid in heat production [18]. Despite its profound effects on BAT stimulation, increasing
exposure to cold temperatures is not a practical method to improve BAT activity for obesity
treatment. Numerous studies have elucidated roles of various dietary and pharmacological
factors that may mimic the effect of cold exposure on BAT. Capsaicin and its analog capsinoids,
compounds found in red peppers, are among the most heavily studied dietary factors
demonstrated to augment BAT-mediated thermogenesis, through activation of the calcium
channel transient receptor potential vanilloid 1 (TRPV1), which subsequently results in b3adrenergic stimulation [43, 44]. Consumption of high doses of capsinoids has demonstrated to
enhance thermogenesis in both rodents and humans, and ingestion of 9 mg per day of capsinoids
for six weeks resulted in greater cold-induced thermogenesis and decreased fat mass in human
subjects [45]. A meta-analysis examining the impacts of capsinoids and capsaicin on humans has
confirmed their ability to enhance energy expenditure and fat oxidation; however, the magnitude
of these effects suggests only a small benefit for long-term weight loss, and many successful
studies were conducted in lean individuals [46]. Fish oil, curcumin, green tea catechins, and
resveratrol are among other dietary compounds with substantial evidence proposing a role in
BAT activation, although numerous others have also been described [47]. Ultimately, there is
significant potential for dietary compounds to act as therapeutic agents through increased BAT
mass and activity, but further research is warranted in order to obtain clinically relevant
outcomes for obesity.

2.2. Polyunsaturated Fatty Acids and their Metabolites
2.2.1. Overview of Polyunsaturated Fatty Acids: Structure, Function, Dietary Sources
Fatty acids are generally categorized based upon the length of their carbon chain and the
number of double bonds. Polyunsaturated fatty acids (PUFAs) are fatty acids that contain at least
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two double bonds on their carbon chain. PUFAs can be further classified into n-3 and n-6
PUFAs, indicating the position of the first double bond is three or six carbons from the methyl
end of the carbon chain, respectively. The 18-carbon n-3 and n-6 PUFAs, alpha-linolenic acid
(ALA) and linoleic acid (LA), are considered essential, indicating they cannot be synthesized in
the body and must instead be obtained through dietary sources. Vegetable oils such as soybean
oil, canola oil, and sunflower oil are especially concentrated in LA but also contain small
proportions of ALA, whereas the opposite is true for flaxseed oil. These essential fatty acids can
also be found in significant quantities in chia seeds, hemp seeds, and walnuts [48, 49].
Longer chain (≥20 carbons) n-3 PUFAs, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), and the n-6 PUFA arachidonic acid (ARA), are more biologically
active and can be synthesized from ALA and LA through multiple steps of elongation and
desaturation [48, 49]. However, this conversion rate is considered to be low in mammals, and
many experts recommend obtaining these longer chain PUFAs directly from the diet to ensure
biological processes are not compromised as a result of deficiency [50-52]. ARA is particularly
abundant in most animal products, such as meat, cheese, and eggs. Insufficient intake of n-6
PUFAs is not a concern for the general population, as typical Western diets are highly
concentrated in both LA and ARA. EPA and DHA, on the other hand, can only be found in coldwater oily fish, and as a result, there is a greater threat for deficiency in cultures where habitual
seafood consumption is not typical [48, 49].
PUFAs are involved in numerous functions throughout the body and have been
extensively studied for their roles as inflammatory mediators. This ability to modulate levels of
inflammation in the body is especially intriguing for therapeutic research, considering many of
the health conditions that plague modern society are provoked and propagated through chronic
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low-grade inflammation. The n-6 PUFAs produce metabolites primarily involved in proinflammatory actions, and conversely, n-3 PUFAs are widely recognized for their antiinflammatory capabilities [53].
PUFAs occupy the sn-2 position of cell membrane phospholipids. Although cell
membrane composition is regulated based on requirements for specific tissues, it is well
established that increasing dietary consumption of certain PUFAs can subsequently elevate the
concentration of that PUFA within cell membranes. This is particularly of interest with regard to
n-3 PUFAs due to their anti-inflammatory roles and the concern for deficiency in typical
Western diets. Insufficient intake of n-3 PUFAs can result in an imbalance that favors proinflammatory mediators [54]. Conversely, consumption of fish oil supplements has been shown
to elevate EPA and DHA concentrations in cell membranes of cells and tissues involved in
inflammation, such as immune cells and adipose tissue, in both a time- and dose-dependent
manner [55-58]. This increase in EPA and DHA coincides with a decrease in ARA [57, 58].
Thus, it is of great interest to examine how these alterations in membrane PUFAs and their
metabolites can elicit various downstream effects on health.
2.2.2. Eicosanoid Production
Upon cleavage by calcium-activated phospholipase A2, PUFAs are liberated from cell
membranes and become subject to metabolism by different classes of enzymes in order to form
bioactive compounds known as eicosanoids. Three major enzyme classes metabolize PUFAs,
including cyclooxygenases (COXs), lipoxygenases (LOXs), and cytochrome P450 (CYP)
monooxygenases. ARA is the most prevalent PUFA in most cell membranes and therefore is the
dominant substrate for eicosanoid synthesis. Metabolism of ARA by COXs produces
prostaglandins (PGs) and thromboxanes (TXs). Among the most biologically relevant is PGE2, a
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potent pro-inflammatory mediator that induces production of inflammatory cytokines by
macrophages, such as tumor necrosis factor (TNF)a, interleukin (IL)-1b, and IL-6. Other key
players include TXA2, an activator of platelet aggregation, and PGI2, involved in vasodilation
and inflammation resolution. LOXs give rise to various leukotrienes (LTs), which are also
pertinent in facilitation of the inflammatory response [48, 59].
EPA is also capable of forming various PGs, TXs, and LTs upon metabolism by COXs
and LOXs, although their biological potency is lesser than those derived from ARA and
consequently, cytokine production and the overall inflammatory influence are attenuated [60].
Remarkably, both EPA and DHA can also produce a different class of eicosanoids when acted
upon by COXs and LOXs that are anti-inflammatory and inflammation resolving, which are
deemed as resolvins (from EPA and DHA), and protectins and maresins (from DHA) [48, 49,
60]. Altered eicosanoid production is a key mechanism through which these long-chain n-3
PUFAs confer benefits for chronic metabolic diseases. However, EPA and DHA exert additional
contributory actions such as decreasing the expression of adhesion molecules involved in
atherosclerosis development, limiting the production of pro-inflammatory transcription factors,
cytokines, and angiogenic growth factors, and reducing lipogenesis via inhibition of sterol
regulatory element binding protein 1c (SREBP1c) [48].
The third pathway of eicosanoid formation, the CYP monooxygenase pathway, is less
characterized than the COX and LOX pathways and has only recently begun to receive
appreciable attention in the literature. CYP hydroxylases can hydroxylate at or near the methyl
end of PUFAs to produce hydroxy fatty acids. Terminal hydroxylation of ARA forms 20hydroxyeicosatetraenoic acid (20-HETE), which has demonstrated pro-inflammatory
capabilities. Elevated plasma and serum levels of this metabolite are associated with increased
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incidence of metabolic disease [61]. CYP epoxygenases oxidize PUFAs across one of their
double bonds, giving rise to various regioisomers of epoxy fatty acids (EpFAs). EpFAs produced
from ARA are known as epoxyeicosatrienoic acids (EETs), whereas EPA and DHA are
metabolized to epoxyeicosatetraenoic acids (EEQs) and epoxydocosapentaenoic acids (EDPs),
respectively. 11,12-EET and 14,15-EET are the most abundantly generated regioisomers from
ARA in most mammalian tissues. In the n-3 varieties, CYP epoxygenases preferentially oxidize
the n-3 bond, resulting in 17,18-EEQ and 19,20-EDP being the predominant n-3 EpFAs formed
[10]. EpFAs have sparked intrigue among researchers due to their observed anti-inflammatory
actions and proposed benefits for numerous diseases [10-13]. The CYP epoxygenase pathway
and its potential impacts for metabolic health will be discussed in greater detail in the following
sections.
2.2.3. CYP Epoxygenase Pathway: CYP Isoforms and Degradation by sEH
CYP enzymes comprise a complex superfamily of genes, with 57 isoforms reported to be
functional in humans [62]. These enzymes function to catalyze the metabolism of various
xenobiotics and endogenous compounds. CYP enzymes are most highly expressed in the liver
but are also expressed in various extrahepatic tissues such as the kidney, heart, skeletal muscle,
adipose tissue, pancreas, and vasculature [63]. Isoforms belonging to the CYP2C and CYP2J
subfamilies are considered the primary epoxygenases responsible for EpFA formation in
mammals. Humans possess four CYP2C isoforms, which are CYP2C8, CYP2C9, CYP2C18, and
CYP2C19 [10, 62]. Murine distribution of isoforms is increasingly complex with 15 described
functional isoforms: Cyp2c29, Cyp2c37, Cyp2c38, Cyp2c39, Cyp2c40, Cyp2c44, Cyp2c50,
Cyp2c54, Cyp2c55, Cyp2c65, Cyp2c66, Cyp2c67, Cyp2c68, Cyp2c69, and Cyp2c70 [10, 62, 64].
Humans only possess one CYP2J isoform, which is CYP2J2. In mice, once again, significant
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allelic expansion has resulted in seven functional isoforms: Cyp2j5, Cyp2j6, Cyp2j8, Cyp2j9,
Cyp2j11, Cyp2j12, and Cyp2j13 [10, 62, 65]. The wide variety of epoxygenase isoforms and
inconsistencies between mice and human varieties creates additional layers of complexity in the
effort to elucidate the key players driving formation of EETs and other EpFAs.
Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose C-terminal domain rapidly
hydrolyzes EpFAs into their corresponding diols following their formation [66]. These diol
counterparts, known as dihydroxyeicosatrienoic acids (DHETs) in the case of EETs, are much
less biologically active and do not exert the same beneficial metabolic effects as EpFAs [10, 67].
In fact, certain diol products of sEH have even illustrated pro-inflammatory potential [61, 68].
EpFAs can be metabolized through other pathways [69]; however, hydrolysis by sEH represents
the dominant pathway of metabolism [67]. Due to these observations, various pharmacological
inhibitors of sEH have been generated in order to stabilize and enhance endogenous EpFA levels
for therapeutic purposes with remarkable levels of efficacy demonstrated in a variety of
conditions, including cardiac arrythmias, hypertension, atherosclerosis, chronic obstructive
pulmonary disease, renal failure, and insulin resistance, among others [70].
2.2.4. Epoxy Fatty Acids: Functions and Mechanisms of Action
EETs are by far the most heavily studied of the CYP-derived EpFAs, and therefore much
of the evidence summarized here regarding EpFAs will be specific to EETs. EETs stimulate
vasodilation, thrombolysis, angiogenesis, and cellular proliferation, and attenuate overall
inflammation and nociception, acting through both autocrine and paracrine processes [63, 67,
71]. EEQs and EDPs are also anti-inflammatory, anti-nociceptive, and vasodilatory, but these n-3
derived epoxides differ from EETs in that they elicit anti-proliferative, proapoptotic, and antiangiogenic effects on target cells [63, 67, 71].
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There are several mechanisms through which these EpFAs exert their biological actions.
EETs are thought to bind to cell-surface receptors in order to activate downstream signal
transduction pathways. For example, EET-dependent vasodilation occurs through activation of
the cAMP/protein kinase A (PKA) pathway. Additional EET actions are mediated through
activation of phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen-activated protein (MAP) kinase,
AMP-activated protein kinase (AMPK), and Src kinase signaling pathways, among others [67,
72]. It has been suggested that a specific EET cell membrane receptor exists; however, there is
currently little evidence to substantiate this claim and the supposed EET receptor has yet to be
identified or cloned [67, 71].
EETs and DHETs can also be taken up directly by cells and incorporated into
phospholipids through a coenzyme-A-dependent mechanism [67, 73, 74]. The physiological
relevance of this incorporation into cell membranes remains to be determined, and it is thought
this may provide an intracellular storage pool of EETs for later usage [71]. Cytosolic fatty acid
binding proteins (FABPs) have been shown to bind EETs and may help to facilitate their uptake
into cells [67, 75]. EETs attached to FABP are also protected from sEH-mediated hydrolysis,
indicating this interaction may serve to prolong EET actions within the cell [76]. In addition to
cell-surface interactions, EET actions are also mediated through interaction with various
intracellular effectors such as ion channels and transcription factors [67]. Most notably, EETs
have illustrated an ability to bind and activate the PPARs [77-80], which likely accounts for
many of their observed metabolic benefits related to adipose tissue and inflammation. A detailed
summary of the evidence surrounding EpFA generation in relation to adipose tissue and obesity
is provided in the next section.
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2.3. CYP Epoxygenase Pathway, White Adipose Tissue, and Obesity
The potent anti-inflammatory capabilities of EpFAs have acquired significant attention
for a potential therapeutic role in the progression of obesity and its associated metabolic diseases.
The effects of EpFAs on body weight and cardio-metabolic health appear to be mediated through
a variety of cell types and tissues in the body, including endothelial cells, hepatocytes, skeletal
muscle, adipose tissue, and immune cells [10-13]. This section will focus particularly on the
evidence pertaining to adipocyte-specific effects of the CYP pathway and the implications for
obesity development.
2.3.1. CYP and sEH Expression in White Adipose Tissue
There are several observations that indicate obesity is associated with dysregulation of
the CYP epoxygenase pathway in white adipose tissue. sEH expression is upregulated upon
differentiation of 3T3-L1 preadipocytes into mature adipocytes while CYP epoxygenase
expression is decreased [14, 81]. As expected, this corresponds with a stark decline in EET levels
as adipocytes develop [14]. This observation is replicated at the human stem cell level, with
CYP2J2 expression and EET levels being shown to decrease as human MSCs become mature
adipocytes [82]. Elevated sEH expression is also present in the adipose tissue of HFD-fed mice
and overweight humans when compared to lean controls, and total adipose sEH activity is higher
in obese mice, even after normalization for body weight [81, 83]. Furthermore, CYP2J2
expression decreased by 71% in the subcutaneous adipose tissue of obese women compared to
lean women [84]. A comprehensive analysis of lipid mediators produced from the COX, LOX,
and CYP pathways in adipose tissue of HFD-fed mice revealed that CYP-derived EpFAs are the
most severely altered in obesity, with almost all types of EpFAs being reduced by 70-90% in the
adipose tissue of obese mice [85]. Together, these observations provide compelling evidence that
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adipocyte-specific expression of CYPs and sEH contribute to decreased EETs in obesity and
implicate a therapeutic role for enhancing EpFA production in adipose tissue. There are three
main approaches used to augment EpFA concentration in order to assess therapeutic outcomes:
overexpression of CYP epoxygenase enzymes, administration of stable EET analogs, and
inactivation of sEH through pharmacological inhibition or targeted gene deletion. The following
sections will outline findings obtained in relation to white adipose tissue and obesity utilizing
these tactics.
2.3.2. CYP Epoxygenase Pathway: Adipogenesis and Obesity
Sustained white adipogenesis is a hallmark of obesity, driving both hyperplasia and
hypertrophy of white adipocytes in order to accommodate excess lipids. Key transcriptional
mediators of this process include PPARg, CCAAT/enhancer-binding protein (C/EBP)a, and
SREBP1c [14, 32]. Accumulating evidence suggests that EETs and other EpFAs elicit regulatory
functions in relation to white adipogenesis. Administration of stable EET analogs dosedependently suppressed differentiation of 3T3-L1 preadipocytes and MSCs into mature
adipocytes with reduced lipid accumulation and decreased gene expression of adipogenic
markers, including PPARg, C/EBPa, SREBP1c, and fatty acid synthase (FAS) [14, 82].
Furthermore, EET analogs given to mice in the drinking water attenuated HFD-induced increases
in body weight, fat mass, and adipocyte size, accompanied by an improvement in glucose
tolerance [14]. Administration of sEH inhibitors and targeted gene deletion of Ephx2, the gene
encoding for the sEH protein, has been shown to produce similar anti-adipogenic effects through
an increase in EpFA bioavailability [14, 82, 86].
The suppressive effect of CYP-derived EpFAs on white adipogenesis is further
corroborated by the study of Cyp2j4 deletion in rats and MSCs [87]. The epoxygenase Cyp2j4 is
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expressed in the major rat organs and shares 79% homology with human CYP2J2 [88].
Remarkably, Cyp2j4-/- MSCs underwent spontaneous adipogenesis, in that these cells
differentiated into mature adipocytes without the addition of adipogenic differentiation media,
displaying significant lipid accumulation and expression of Fabp4. Moreover, WAT from
Cyp2j4-/- rats exhibited elevated expression of PPARg and C/EBPa compared to wild-type (WT)
control rats [87].
CYP2J2 gene therapy in mice, which resulted in significant CYP2J2 protein expression in
adipose tissue, was confirmed to elevate circulating EETs. Overexpression of this key human
epoxygenase mitigated the burden of a HFD, with significantly reduced total body weight,
adiposity, serum triglycerides and cholesterol in the transgenic mice [89]. These observed effects
on cholesterol metabolism appear to be at least partially due to adipocyte-derived EpFAs, as
incubation of 3T3-L1 differentiated adipocytes with an sEH inhibitor enhanced CD36-mediated
recognition and degradation of oxidized low-density lipoproteins, and improved cholesterol
efflux to form high-density lipoproteins through upregulation of ATP-binding cassette
transporter (ABCA1) [90]. Moreover, this enhancement of reverse cholesterol transport through
sEH inhibition was also demonstrated in adipocytes in vivo [91].
However, effects on white adipose tissue are not solely due to adipocyte-specific EpFA
production, as other studies have demonstrated similar outcomes mediated through epoxygenase
overexpression in other organs. For example, a similar study examining CYP2J2 gene therapy in
diabetic mice reported that CYP2J2 protein expression was primarily present in the liver, with no
detectable levels in adipose tissue. Despite this, these transgenic mice still experienced a marked
decrease in body weight, serum triglycerides, and cholesterol levels [92]. Moreover, endothelialspecific overexpression of CYP2J2 in mice significantly attenuated HFD-induced increases in
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body weight and adiposity when compared to WT controls, while also improving vascular
dysfunction [93]. The anti-adipogenic effects of epoxygenase overexpression may be partially
attributed to enhanced lipid oxidation, as endothelial CYP2J2 overexpression has also been
shown to activate the AMPK pathway with increased phosphorylation of acetyl-CoA
carboxylase (ACC) and increased expression of carnitine palmitoyltransferase I (CPT1) and
PPARa [94]. The studies of endothelial-specific CYP2J2 overexpression implicate EpFAs from
the endothelium may evoke paracrine effects on adipocytes. Given that endothelial cells
comprise a significant portion of the adipose stromal vascular fraction [95], it is likely that
EpFAs can arise from these neighboring cells in order to exert their functional effects in
adipocytes.
It is important to note that physical outcomes of altering EpFA bioavailability in vivo on
adiposity are not apparent until subjects are placed under significant metabolic stress from
energy-dense diets or advancing age. While endothelial CYP2J2 overexpression in mice
attenuated HFD-induced increases in body weight and adiposity compared to WT controls, no
differences between groups were detected when mice were fed regular chow [94]. Similarly,
these transgenic mice were also protected from aging-induced increases in fat mass and
adipocyte size, but no differences in these parameters were present in the young mice [96].
Cyp2j4-/- rats fed a high-fat, high-sugar cafeteria diet (CAF) displayed increased body weight and
fat mass gain with greater adipocyte size compared to WT rats fed the same diet, and these
effects were also mirrored under the pressure of aging [87]. Together, these outcomes
demonstrate the beneficial impacts of CYP epoxygenase enzymes on body weight and adiposity
under circumstances of metabolic stress.
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EETs have been demonstrated to bind and activate PPARg, so it is rather surprising that
the anti-adipogenic effect of increased EpFAs seems to be at least partially facilitated through
downregulation of PPARg in WAT under metabolic stress, as summarized above. It has been
speculated that EET interaction with ERK, AMPK, and cAMP/PKA signaling pathways may
play a role to evoke this downregulation of adipogenic transcription factors, particularly in the
early phases of adipogenesis [14]. However, the inhibitory effect of EETs and other EpFAs on
white adipogenesis is not straightforward and some findings are even contradictory. One study
demonstrated that EET analogs in the presence of an sEH inhibitor activated PPARg and
increased Fabp4 mRNA expression in 3T3-L1 preadipocytes, a general marker of adipocyte
differentiation [77]. Furthermore, CYP2J2 overexpression in the livers of diabetic mice increased
PPARg mRNA and protein levels by 4.5-fold, potentially as a means to attenuate dyslipidemia
present in diabetes [92]. Therefore, the effects of EpFAs on PPARg expression are likely
contingent upon interaction of EpFAs with other signaling pathways and may be influenced by
the tissue microenvironment, and further studies are needed to fully elucidate these complex
interactions.
2.3.3. CYP Epoxygenase Pathway: Inflammation in White Adipose Tissue
Under circumstances of chronic energy surplus, the expansion of WAT exceeds the rate
of neovascularization, resulting in a state of localized hypoxia and fibrosis. Reduced tissue
plasticity and increased mechanical stress ultimately triggers a persistent inflammatory response,
with altered adipokine secretion and infiltration of macrophages into adipose tissue. Further
caloric overload eventually exceeds the storage capacity in WAT, leading to ectopic lipid
accumulation in tissues such as the liver, skeletal muscle, and heart, a phenomenon commonly
referred to as lipotoxicity. These alterations in adipocyte function and structure provoke the
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downstream cardio-metabolic abnormalities characteristic of many chronic diseases, such as
insulin resistance and endothelial dysfunction [97-100].
In the inflammatory state, altered adipokine secretion is characterized by a stark increase
in TNFa accompanied by a decline in adiponectin levels [97]. TNFa is known to stimulate the
activation of nuclear factor kappa B (NF-kB), a central mediator of the inflammatory response
that prompts expression of various pro-inflammatory genes [101]. Inhibition of NF-kB is a key
mechanism through which EpFAs exert their anti-inflammatory actions [70]. EpFAs can block
nuclear translocation of NF-kB through inhibition of IkB kinase and can also indirectly reduce
its transcriptional activity through activation of PPARg [77, 80, 102]. CYP2J2 overexpression,
sEH inhibition, and EET infusion via osmotic mini pumps have each demonstrated to mitigate
HFD-induced activation of NF-kB and MAPK signaling pathways in WAT [89]. This function
of EpFAs demonstrates a manner through which these lipid mediators can alleviate the
inflammatory consequences of obesity within adipose tissue.
Additionally, EpFAs have been shown to reverse the decline in adiponectin associated
with inflammatory WAT. Adiponectin reduces inflammatory cytokines and oxidative stress and
helps to regulate glucose and lipid metabolism [103]. Incubation of differentiated 3T3-L1 cells
with an EET analog increased adiponectin levels in the culture medium and decreased the proinflammatory cytokines IL-1a and IL-6 [104]. Similarly, treatment with an EET analog reversed
the HFD-induced decrease of serum adiponectin in mice, with a reduction in serum TNFa and
IL-6 [105]. Incubation of lipopolysaccharide (LPS)-induced 3T3-L1 mature adipocytes with an
sEH inhibitor dose-dependently enhanced adiponectin levels, and this effect was blocked by the
addition of the PPARg antagonist GW9662, indicating that upregulation of adiponectin occurs in
a PPARg-dependent manner [90]. Furthermore, Cyp2j3 gene delivery in rats and 3T3-L1 cells
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stressed by a HFD or thapsigargin resulted in increased adiponectin levels, which was mediated
through alleviation of endoplasmic reticulum (ER) stress [106]. sEH inhibition or deficiency has
also been reported to attenuate HFD-induced ER stress in the adipose tissue of mice [83].
CYP2J2 overexpression and sEH inhibition have also been shown to reduce macrophage
infiltration and fibrosis within the WAT of HFD-fed mice, with downstream effects on insulin
sensitivity [89, 93, 107]. Furthermore, an increase in EpFA bioavailability through these means
hindered the switch of macrophages to the classically active macrophage (M1) phenotype
associated with WAT inflammation and preserved the alternatively activated macrophage (M2)
phenotype. Conversely, Cyp2j4-/- rats fed CAF displayed increased crown-like structures and
fibrotic collagen within WAT compared to WT mice on the same diet. These rats also
experienced ectopic lipid accumulation particularly in the liver, indicative of severely overloaded
and inflamed WAT [87]. Collectively, these findings indicate the anti-inflammatory activity of
EETs and other EpFAs can ultimately aid in reversal of the altered adipokine production and
macrophage infiltration characteristic of dysfunctional WAT, demonstrating ample significance
for prevention of obesity-associated metabolic diseases.
2.3.4. CYP Epoxygenase Pathway: Browning of White Adipose Tissue
In addition to the anti-adipogenic and anti-inflammatory functions of EpFAs in WAT,
these eicosanoids have also been reported to stimulate mitochondrial biogenesis and other
markers of WAT browning. EETs and other EpFAs are thought to induce PGC-1a activation,
resulting in downstream effects on mitochondrial function, thermogenesis, and overall energy
expenditure. Stable EET analogs have been demonstrated to increase white adipocyte expression
of PGC-1a, PRDM16, UCP1, uncoupling protein-2 (UCP2), and cytochrome c oxidase subunit 1
(COX-1), both in vitro and in vivo [104, 108, 109, 110]. Additionally, EET analogs normalized
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VO2 levels and the respiratory quotient in HFD-fed mice, with an elevation of mitochondrial
proteins [108]. Outcomes on thermogenic and mitochondrial markers are PGC-1a-dependent, as
these effects are diminished in PGC-1a-deficient cells and animals [104, 108, 109, 110]. CYP2J2
overexpression and sEH inhibition also have been shown to elicit similar elevations in PGC-1a,
UCP1, and UCP2 in WAT of HFD-fed mice [89, 93, 111]. Ultimately, the promotion of WAT
browning is likely a manner through which EpFAs reduce adiposity under metabolic stress,
working together with the other described anti-inflammatory and anti-adipogenic functions to
combat obesity and its related diseases.

2.4. CYP Epoxygenase Pathway and Brown Adipose Tissue
2.4.1. Evidence for a Role in Brown Adipose Tissue
Despite the described probable functions of EpFAs in browning and energy expenditure,
studies examining the CYP pathway specifically in classical BAT are extremely limited. BAT is
highly vascularized to facilitate substrate delivery and heat transmission, with endothelial cells
representing the most abundant cell type within BAT [6]. Given that elevated EpFAs from the
endothelium seemingly evoke paracrine effects on WAT, it can be presumed these endothelialderived EpFAs play additional roles in BAT.
Brown adipocytes also produce EpFAs, which may contribute to favorable metabolic
outcomes. Our recent data illustrated that sEH expression is upregulated in in vitro brown
adipogenesis and in the BAT of diet-induced obese mice, mimicking the pattern observed in
white adipocytes [112]. Furthermore, we found that sEH inhibition by trans-4-{4-[3-(4trifluoromethoxy-phenyl)-ureido]-cyclohexyloxy-benzoic acid (t-TUCB) dose-dependently
promoted brown adipogenesis in vitro and increased protein expression of genes imperative for
lipid metabolism in the BAT of diet-induced obese mice [112]. A different study examining sEH
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inhibition in diet-induced obesity reported a 50% increase in UCP1 protein expression in the
interscapular BAT (iBAT) of mice, accompanied by enhanced metabolic rate and weight loss
[113]. Usage of a different sEH inhibitor in another study increased the iBAT mass of fat-1 mice,
which are mice that express an n-3 desaturase that elevates endogenous cell membrane n-3
PUFAs [107]. Additionally, EET analogs have been shown to upregulate UCP1 mRNA
expression in the BAT of HFD-fed mice [14]. Collectively, these data indicate the beneficial
metabolic effects of EpFAs may be partially mediated through enhanced BAT development and
activation.
It is worth noting that in the study which reported increased iBAT mass with an sEH
inhibitor, the effect on BAT was only apparent in the fat-1 mice and not the WT mice [107].
These fat-1 mice presented with significantly elevated n-3-derived EpFAs due to increased cell
membrane n-3 PUFAs, suggesting that n-3-derived EpFAs such as 17,18-EEQ and 19,20-EDP
may be more important for the promotion of BAT development and activity rather than ARAderived EETs. This hypothesis is further substantiated when considering that fish oil is believed
to enhance brown and beige fat development and thermogenesis based on numerous studies
[114-118], and this may occur in an adipocyte-autonomous manner, given that EPA stimulates
brown adipogenesis in vitro [119-121]. Primary mechanisms cited for these effects of fish oil
include EPA- and DHA-mediated activation of TRPV1 and G protein-coupled receptor 120
(GPR120) [122]. Perhaps, fish oil partially exerts these effects through increased formation of n3-derived EpFAs, potentially inducing more potent activation of TRPV1 and GPR120 with
subsequent thermogenic stimulation. Indeed, it has been postulated that many of the
cardioprotective properties of fish oil may be attributed to their epoxide metabolites [123],
suggesting potential for a similar role in BAT. Elevation of cell membrane n-3 PUFAs from fish
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oil supplementation has been shown to increase serum n-3 EpFAs more than any other lipid
mediator [124], further validating the relevance of these eicosanoids in facilitating the effects of
fish oil. Overall, it appears likely that EpFAs play a significant role in brown adipocytes, and
further studies examining the CYP pathway in BAT are warranted to elucidate these functions
and their relation to obesity pathogenesis.
2.4.2. The Research Gap
In summary, it has been well established that the CYP epoxygenase pathway holds
therapeutic promise for obesity and its related metabolic diseases, and that these effects are
administered at least partially in an adipocyte-autonomous manner. CYP overexpression is
capable of producing these favorable outcomes through an increase in EpFA bioavailability.
However, the vast array of CYP isoforms makes identification of the primary epoxygenases
driving these metabolic effects to be much more complex and challenging. There are currently
very limited data examining CYP expression in white adipocytes, and a comprehensive analysis
of all known epoxygenase isoforms has not been conducted. Additionally, to our knowledge, no
studies have determined which CYP isoforms are expressed specifically in BAT, and the role of
CYP epoxygenase expression in brown adipogenesis has not yet been explored.
In this thesis, we sought to characterize adipocyte CYP epoxygenase expression
throughout adipogenesis and in diet-induced obesity. This was accomplished through a
comprehensive analysis of Cyp2j and Cyp2c mRNA expression in brown and white adipocytes
of murine and human origin throughout differentiation, and in the BAT and WAT of mice fed
HFD and regular chow. Furthermore, we began to elucidate the role of the CYP pathway in
brown adipocytes through modulation of CYP epoxygenase expression in murine and human
brown adipogenesis. Collectively, these data contribute to our understanding of the CYP

24

epoxygenase pathway in adipocytes and suggest a role of these enzymes in brown adipogenesis,
further contributing to our comprehension of how EpFAs can help regulate overall metabolic
homeostasis.
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CHAPTER III
MATERIALS AND METHODS
3.1. Materials and Reagents
Anti-UCP1 antibody was purchased from Sigma-Aldrich (St. Louis, MO). Anti-PGC-1a
antibody was purchased from Millipore (Temecula, CA). Anti-CYP2J2 antibody was purchased
from Kerafast (Boston, MA). Anti-PPARg, anti-Myc-Tag, anti-ERK1/2, horseradish peroxidaseconjugated goat anti-rabbit, and horseradish peroxidase-conjugated goat anti-mouse antibodies
were purchased from Cell Signaling Technology (Danvers, MA).
The Myc-DDK-tagged Cyp2j13 cDNA plasmid and empty vector control (pCMV6) were
purchased from OriGene (Rockville, MD). The lentiviral particles against mouse Cyp2j13 and a
non-targeting scrambled control were obtained from MISSION Sigma-Aldrich (St. Louis, MO).
The CYP2J2 cDNA plasmid was a gift from Dr. Ahmed Bettaieb at the University of Tennessee
Knoxville, and the empty vector pSBtet-Pur was a gift from Eric Kowarz [125] (Addgene
plasmid # 60507; http://n2t.net/addgene:60507; RRID:Addgene 60507). The pSBtet-Pur-CYP2J2
construct was generated by PCR amplifying CYP2J2 full cDNA fragment flanked with two
different SfiI sites followed by ligation into the SfiI pre-cut pSBtet-Pur vector. The complete
CYP2J2 cDNA sequences in pSBtet-Pur were confirmed by sequencing.

3.2. Cell Culture and Differentiation
The murine brown preadipocyte cell line was a gift from Dr. Johannes Klein (University
of Lubeck, Lubeck, Germany), and was generated from the interscapular brown adipose tissue of
newborn C57BL/6J mice [126]. The cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 20% fetal bovine serum (FBS) (Atlanta Biologicals,
Flowery Branch, GA) in a humidified 37ºC and 5% CO2 incubator until they reached confluence
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(designated as day 0 (D0)). The cells were then induced to differentiate in differentiation media
containing DMEM supplemented with 20% FBS, 1 nM T3, and 20 nM insulin every 2 days for 6
days. Select cells received induction media containing differentiation media supplemented with
0.125 mM indomethacin, 2 µg/ml dexamethasone, and 0.5 mM 3-isobutyl-1-methylxanthine
(MIX) for 24 hours prior to being changed into differentiation media to induce a stronger degree
of differentiation.
The murine 3T3-L1 cell line was obtained from ATCC (Manassas, VA). The cells were
maintained in DMEM supplemented with 10% calf serum (Hyclone, Logan, UT) until they
reached confluence. Preadipocytes were then induced to differentiate with differentiation media
containing DMEM supplemented with 10% FBS, 1 µM dexamethasone, 10 µg/ml insulin, and
0.5 mM MIX for 3 days (D0-D3). Media were subsequently changed to DMEM with 10% FBS
and 10 µg/ml insulin for an additional 2 days (D4-D5). Cells were then maintained in DMEM
with 10% FBS until fully differentiated on D7.
The human brown cell line was a gift from Dr. Yu-hua Tseng at Joslin Diabetes Center.
Cells were cultured and differentiated, as previously described [127]. Briefly, the preadipocytes
were cultured in DMEM supplemented with 10% FBS until confluency was achieved. Cells were
then induced to differentiate in DMEM supplemented with 10% FBS, 0.5 µM insulin, 33 µM
biotin, 17 µM pantothenate, 0.1 µM dexamethasone, 2 nM T3, 500 µM MIX, 30 µM
indomethacin, and 5 µM rosiglitazone. Media were replaced every 3 days until cells were fully
differentiated at 3 or 4 weeks. For the CYP2J2 overexpression experiments, human brown cells
received either 1 µg/ml doxycycline or the vehicle control (water) in the media at 48 hours prior
to confluency, and then with every medium change thereafter in order to induce stronger
expression of human CYP2J2.
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293T (human embryonic kidney cells) were obtained from Sam Lee at Beth Israel
Hospital (Boston, MA) [128] and were used to generate positive controls for the CYP2J13 and
CYP2J2 protein expression. The cells were maintained in DMEM with 10% FBS.

3.3. Animals
All mice studies were approved by the Institutional Animal Care and Use Committee at
the University of Tennessee. C57BL/6J mice were purchased from Jackson Laboratory (Bar
Harbor, ME). The diet-induced obese mice and their chow-fed controls have been described
elsewhere [129, 130]. Briefly, six-week old male mice were fed either a HFD (60% kcal from
fat, D12492) (Research Diets Inc., New Brunswick, NJ) or regular chow (RC) for 20 weeks
before sacrifice at 26 weeks of age. Upon sacrifice, iBAT, epididymal and subcutaneous inguinal
WAT (eWAT and iWAT) were excised and immediately snap-frozen in liquid nitrogen and
stored at -80ºC until analysis.

3.4. Lipofectamine Transfection
Murine and human brown preadipocytes were seeded in 12- or 6-well plates at ~50%
confluency. Cells were then transfected using Lipofectamine 3000 and Plus reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions, and were split into selection media
48 hours later. Cyp2j13-stably transfected murine brown preadipocytes were selected for two
weeks with 600 µg/ml neomycin. Individual stable clones were used for analysis. CYP2J2-stably
transfected human brown preadipocytes and 293T cells were selected for two weeks with 2
µg/ml puromycin. Stably transfected pooled cells were used for analysis. 293T cells transfected
with Cyp2j13 did not undergo selection and were immediately harvested at 48 hours after
transfection.
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3.5. Lentiviral shRNA Particle Infection
Murine brown preadipocytes were seeded at ~50% confluency in 6-well plates. Cells
were then transduced with lentiviral particles against mouse Cyp2j13 or a scrambled nontargeting control (MISSION Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s
instructions, and were split into selection media after 48 hours. Stably infected cells were
selected for two weeks with 600 µg/ml neomycin. Individual stable clones were used for
analysis.

3.6. RNA Preparation and Quantitative Real-Time PCR Analysis
Total RNA was extracted using TRI reagent (Molecular Research Center, Cincinnati,
OH) according to the manufacturer’s instructions. Total RNA yield was quantified with
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Reverse
Transcription was performed using a High Capacity cDNA Reverse Transcription Kit (Thermo
Scientific, Pittsburgh, PA) according to the manufacturer’s instructions. mRNA expression of
target genes and the housekeeping gene 36B4 (a ribosomal protein that is a component of the
60S subunit) were measured quantitatively using the PowerUp SYBR master mix (Applied
Biosystems, Austin, TX) and gene-specific primers (primer sequences available upon request).
PCR reactions were run in a 96-well format using an ABI 7300HT instrument. Cycle conditions
were 50ºC 2 min, 95ºC 2 min, 40 cycles of 95ºC for 15 s, then 60ºC for 1 min. Relative gene
expression was calculated using the 2-DCt method, after normalization to the housekeeping gene
36B4.

3.7. Western Blot Analysis
Total cell lysates were prepared using 1xRIPA lysis buffer (Cell Signaling, Danvers,
MA). Protein concentrations were quantified using the BCA assay kit (Thermo Scientific,
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Waltham, MA). Proteins were separated on a 10% SDS-PAGE gel and then transferred to
polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA). Membranes were blocked in
TBST buffer (20 mM Tris Base, 137 mM NaCl, and 0.1% Tween 20 (pH 7.4)) containing 5%
nonfat milk. Membranes were then immunoblotted with the primary antibodies at 4ºC overnight,
followed by 1-hour incubation with secondary antibodies conjugated with horseradish peroxidase
at room temperature. Protein bands were visualized using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific, Pittsburgh, PA). Band densitometry was
quantified using the ChemiDocXRS+ system with Image Lab software (Bio-Rad, Hercules, CA).

3.8. Statistical Analysis
Statistical analysis was performed using SigmaPlot 14.0 (Systat Software, San Jose, CA).
One-way ANOVA followed by the Holm-Sidak method was performed in the time course
studies to determine differences in group means compared to cells collected on day 0. Murine
brown cells receiving induction media and those receiving only differentiation media were
compared separately to day 0. One-way ANOVA followed by the Student-Newman-Keuls
method for multiple groupwise comparisons was conducted to determine differences in group
means compared to the control groups in the animal studies and Cyp2j13 overexpression and
knockdown experiments. In the studies of CYP2J2 overexpression in human brown cells, twoway ANOVA followed by the Student-Newman-Keuls method was performed to determine the
differences between CYP2J2 overexpression and the empty vector controls and between
treatment with doxycycline and the vehicle control. The level of significance was set at p < 0.05.
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CHAPTER IV
RESULTS AND DISCUSSION
4.1. Results
4.1.1. CYP Epoxygenase Expression in Murine Brown Adipocyte Differentiation
We first examined CYP epoxygenase expression in murine brown adipocyte
differentiation. Brown adipocyte marker genes Ucp1, Pgc-1a, Pparg, Prdm16, and cell deathinducing DFFA like effector A (Cidea) were significantly increased in a time-dependent manner
during the course of differentiation, and their expression were significantly higher in cells that
received induction media (Figure 1A). mRNA expression of a total of 19 murine Cyp2j and
Cyp2c isoforms (Cyp2j5, Cyp2j6, Cyp2j7, Cyp2j8, Cyp2j9, Cyp2j11, Cyp2j12, Cyp2j13,
Cyp2c29, Cyp2c37, Cyp2c38, Cyp2c39, Cyp2c40, Cyp2c44, Cyp2c50, Cyp2c54, Cyp2c55,
Cyp2c65, and Cyp2c66) were examined in the murine brown cells. Of these, Cyp2j5, Cyp2j7,
Cyp2j11, Cyp2j12, Cyp2c29, Cyp2c38, and Cyp2c40 were not detectable in all or a majority of
the time points examined. mRNA expression levels of the remaining Cyp2j isoforms and select
Cyp2c isoforms during differentiation are shown (Figure 1B, C). Interestingly, expression of all
the Cyp2j isoforms were either elevated or not changed in the cells receiving only differentiation
media but suppressed in the more strongly differentiated cells that received induction media
(Figure 1B). The cells receiving only differentiation media had statistically significant elevations
in mRNA levels of Cyp2j6, Cyp2j9, and Cyp2j13 compared to day 0, with an upward trend also
observed with Cyp2j8. Conversely, in the cells receiving induction media, mRNA expression of
Cyp2j6, Cyp2j9, and Cyp2j13 significantly decreased compared to day 0, with a downward trend
in Cyp2j8 mRNA levels. (Figure 1B).
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Similar outcomes were observed in the Cyp2c isoforms, with slightly elevated or
unaffected mRNA levels in cells receiving only differentiation media, and lower expression in
cells receiving the induction media (Figure 1C). However, expression patterns were not as
consistent between samples as with the Cyp2j isoforms. Of the tested isoforms, Cyp2c44
displayed a unique expression pattern, which was significantly elevated both in cells receiving
only differentiation media and receiving induction media (Figure 1C). mRNA levels of Cyp2c37,
Cyp2c50, Cyp2c55, Cyp2c65, and Cyp2c66 were increased in cells receiving only differentiation
media, reaching statistical significance for Cyp2c55 (p < 0.05). Similarly, mRNA levels of these
Cyp2c isoforms showed a downward trend in cells receiving the induction media. Overall, these
data demonstrate that mRNA levels of tested murine Cyp2j and 2c isoforms are inversely
correlated with the degree of brown adipocyte differentiation, suggesting roles of these enzymes
in brown adipogenesis.
Next, we sought to compare the relative abundance of mRNA levels of the examined
CYP isoforms both in the brown pre- and differentiated adipocytes. Of the Cyp2j isoforms,
Cyp2j6 mRNA levels were the most abundant, followed by Cyp2j9, then Cyp2j13, and Cyp2j8.
Cyp2c65 mRNA levels were the most abundant of the Cyp2c isoforms, followed by Cyp2c66,
and Cyp2c55 expression was the least pronounced. Between both Cyp2j and Cyp2c subfamilies,
Cyp2c65 was the most highly expressed (Figure 1D).
4.1.2. CYP Epoxygenase Expression in 3T3-L1 Adipocyte Differentiation
After thoroughly studying CYP epoxygenase expression patterns in brown adipocyte
differentiation, we then examined the expression of these genes in 3T3-L1 white adipocyte
differentiation. Strong differentiation was indicated by time-dependent increases in mRNA levels
of adipogenic markers Fabp4, Fasn, Pparg, C/ebpa, and stearoyl-Coenzyme A desaturase 1

32

(Scd1) during the course of differentiation (Figure 2A). Consistently, Cyp2j mRNA levels,
except for Cyp2j8, appeared to be decreased at day 3 and 5 compared to that of day 0, but were
increased by day 7, with statistically significant elevations observed in Cyp2j8 and Cyp2j13 (p <
0.01) (Figure 2B). Interestingly, while majority of Cyp2j isoforms decreased at day 3, this
regression appeared to be compensated for by an enhancement of Cyp2c mRNA expression.
mRNA levels of Cyp2c37, Cyp2c50, Cyp2c55, Cyp2c65, and Cyp2c66 each showed pronounced
and statistically significant elevations at day 3 (Figure 2C). The only tested isoform showing a
different pattern was Cyp2c44, which increased throughout differentiation (Figure 2C). Similar
to the Cyp2j isoforms but to a greater degree, expression of all the Cyp2c isoforms were elevated
in the fully mature white adipocytes at day 7 compared to the preadipocytes (day 0). Overall,
these data demonstrate that mRNA levels of tested murine Cyp2j and 2c isoforms are positively
correlated with the degree of white adipocyte differentiation. Notably, the relative mRNA
abundance of the tested CYP genes in the white adipocytes followed the same pattern as in the
brown adipocytes, suggesting that similar CYP isoforms are the most prevalent EpFA producers
in both brown and white adipocytes (Figure 2D). However, unlike the brown adipocytes, the
relative Cyp2j6 mRNA level was overall the most abundant among both the Cyp2j and Cyp2c
isoforms in the 3T3-L1 cells (Figure 2D).
4.1.3. CYP Epoxygenase Expression in Human Brown Adipocyte Differentiation
After surveying CYP expression patterns in murine brown and white adipocytes, we next
sought to examine the mRNA expression of human CYP isoforms in human brown adipocyte
differentiation. The human brown preadipocytes achieved a high level of differentiation by week
4, displaying significant increases in mRNA levels of brown adipocyte marker genes UCP1,
PGC-1a, and PPARg (Figure 3A). Interestingly, mRNA levels of CYP2C isoforms were more
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pronounced in the more differentiated state, with statistically significant elevations observed at
week 4 in each of the four isoforms (Figure 3B). mRNA levels of CYP2C9 and CYP2C18
showed approximately 50-fold increases of mRNA levels at week 4 compared to day 0 (p <
0.001). This pattern contrasts slightly with the observed decline in Cyp2c mRNA levels in the
murine brown cells receiving the induction media but aligns with the slight increase observed in
the cells receiving only differentiation media. Considering these human brown cells did not fully
differentiate to the extent of the murine brown cells receiving induction media, this observation
suggests a bell-shaped pattern between CYP mRNA expression and brown adipocyte
differentiation, in that enhanced mRNA levels are associated with a smaller degree of
differentiation, but these levels are decreased as stronger degrees of differentiation are achieved.
Interestingly, while CYP2C mRNA levels increased during human brown differentiation,
CYP2J2 displayed an opposing pattern. CYP2J2 was found to be minimally expressed in our
human brown cell line, and these low levels completely diminished with no detectable levels
observed by week 4 (Figure 3B). Of the human CYP isoforms, CYP2C19 was the most abundant,
followed by CYP2C18, then CYP2C9, CYP2C8, and finally CYP2J2 (Figure 3C).
4.1.4. CYP Epoxygenase Expression in Diet-induced Obesity
In order to characterize CYP expression patterns in adipose tissue under circumstances of
metabolic dysfunction, we next examined relative mRNA levels of these enzymes in adipose
tissue from HFD-induced obese mice compared to RC-fed controls. Interestingly, mRNA levels
of Cyp2j isoforms in the iBAT trended upwards in HFD-fed mice compared to controls, but
statistical significance was only achieved for Cyp2j9 (p < 0.05) (Figure 4A). Cyp2c mRNA
expression in the iBAT displayed high levels of variation among individual mice and among
isoforms (Figure 4B). There were no clear and consistent patterns across isoforms observed in
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the eWAT, but Cyp2j6 mRNA expression was significantly elevated in the HFD-fed mice,
whereas Cyp2c65 and Cyp2c66 mRNA levels were significantly suppressed (p < 0.05). Cyp2j13
mRNA level also trended downwards, but this did not reach statistical significance (Figure 4C,
D). In the iWAT, mRNA expression of Cyp2j isoforms again appeared to trend upwards in the
HFD-fed mice, with Cyp2j8 reaching statistical significance (p < 0.05) (Figure 4E). No
significant differences in iWAT Cyp2c mRNA levels were detected between groups (Figure 4F).
Cyp2c55 expression was also examined in the tissue samples, but mRNA levels were primarily
undetectable and therefore the data is not shown. Overall, these data suggest that obesity may be
associated with dysregulation of CYP expression in different adipose tissue depots.
4.1.5. Cyp2j13 Overexpression Suppresses Murine Brown Adipocyte Differentiation
Considering that Cyp2j isoforms displayed more consistent but differential mRNA
expression patterns in brown vs. white adipocyte differentiation in the cell culture studies, we
chose to specifically focus on Cyp2j isoforms in brown adipocyte differentiation for the next
portion of our study. Cyp2j13 was selected for further investigation due to its unique mRNA
expression pattern showing an upward trend in the iBAT and a downward trend in the eWAT of
HFD-fed mice. We first examined the impact of Cyp2j13 overexpression on murine brown
adipogenesis. CYP2J13 protein expression was increased by ~6-fold in the murine brown
preadipocytes stably transfected with the Cyp2j13 expression plasmid (pCMV6-Cyp2j13)
compared to preadipocytes stably transfected with the empty vector (pCMV6) (Figure 5A). At
day 6 of differentiation, Cyp2j13 mRNA expression was increased by ~16-fold in the
overexpressing murine brown adipocytes (Figure 5C). Remarkably, overexpression of this
murine epoxygenase induced a strong suppression of brown adipocyte differentiation. At day 6
of differentiation, Cyp2j13 overexpressed brown cells displayed significantly reduced lipid
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accumulation (Figure 5B left panel) with an approximate 50% decrease in oil red O (ORO)
absorbance (p < 0.001) (Figure 5B right panel). Furthermore, mRNA expression of key brown
marker genes Ucp1 and Cidea and general adipocyte differentiation markers Pparg and Fabp4
were significantly suppressed with Cyp2j13 overexpression (p < 0.01, p < 0.001, and p < 0.05,
respectively) (Figure 5C). Protein levels of UCP1 and PPARg were also consistently suppressed
in the Cyp2j13 overexpressing cells (p < 0.001). In contrast, mRNA expression of the
thermogenic marker Pgc-1a was significantly elevated in the Cyp2j13 overexpressing cells
(Figure 5C), but protein expression was significantly reduced (p < 0.05) (Figure 5D), suggesting
differential regulation of Pgc-1a expression at the mRNA and protein levels by Cyp2j13
overexpression in brown adipocytes. Ppara mRNA levels also trended downwards in the
Cyp2j13 overexpressing cells, but this did not reach statistical significance (Figure 5C).
Together, these findings suggest that increasing Cyp2j13 expression may repress brown
adipocyte differentiation.
4.1.6. Cyp2j13 Knockdown Enhances Murine Brown Adipocyte Differentiation
We next utilized lentiviral-mediated knockdown of Cyp2j13 to assess if the opposite
outcome could be produced. Due to the lack of an available antibody specific for CYP2J13,
knockdown efficacy was validated solely on the mRNA level. mRNA expression of Cyp2j13 in
the Cyp2j13 knockdown (KD) brown preadipocytes was reduced by ~70% compared to cells
infected with the scrambled non-targeting control (p < 0.01) (Figure 6A). mRNA expression of
the brown marker gene Cidea and general differentiation markers Fabp4 and Fasn were
significantly enhanced in the Cyp2j13 KD cells on day 6 of differentiation (p < 0.001, p < 0.05,
and p < 0.01, respectively) (Figure 6B). Pgc-1a mRNA expression also trended upwards, and
PGC-1a protein levels displayed a significant elevation (p < 0.001) (Figure 6B, C). There were
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no observed differences in Ucp1 mRNA expression between the two cell populations, however, a
significant increase in UCP1 protein expression was observed (p < 0.01) (Figure 6C). In contrast,
mRNA levels of both Pparg and Ppara were significantly reduced in the Cyp2j13 KD cells (p <
0.01), but protein levels of PPARg were unaffected. Overall, these data appear to corroborate the
suppressive effect of Cyp2j13 overexpression on brown adipogenesis and suggest that Cyp2j13
may be a negative regulator of murine brown adipogenesis.
4.1.7. CYP2J2 Overexpression Does Not Affect Human Brown Adipocyte Differentiation
In attempt to gain insight into the role of CYP epoxygenases in human brown
adipogenesis, we next analyzed the impact of CYP2J2 overexpression on human brown
adipocyte differentiation. Human brown preadipocytes were stably transfected with the CYP2J2
expression plasmid (pSBtet-CYP2J2) or the empty vector (pSBtet). Robust CYP2J2 expression
was induced by treatment with 1 µg/ml doxycycline and compared with cells receiving the
vehicle control (water). After 48 hours of treatment with doxycycline or water, only the human
brown preadipocytes transfected with CYP2J2 and treated with doxycycline demonstrated
significant CYP2J2 protein expression (Figure 7A). However, mRNA analysis in the human
brown adipocytes after differentiation for three weeks demonstrated that cells transfected with
the CYP2J2 plasmid still displayed a significant induction of CYP2J2 mRNA expression without
doxycycline, although not to the extent of the cells which received doxycycline. Of the CYP2J2
transfected cells, those receiving water experienced a ~2600-fold increase in CYP2J2 mRNA
expression compared to the empty vector controls treated with water, while cells treated with
doxycycline displayed nearly a 195,000-fold increase (p < 0.001) (Figure 7B). These strong
elevations of CYP2J2 expression in the differentiated human adipocytes were also confirmed at
the protein level (Figure 7C). Surprisingly, despite the highly successful induction of CYP2J2
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overexpression in the human brown adipocytes, no visible differences in differentiation potential
were observed between the four groups after differentiation for three weeks. CYP2J2
overexpression did not change UCP1, PPARg, FABP4, FASN, or PPARa mRNA expression
levels. However, CYP2J2 overexpression did elicit a significant reduction in PGC-1a mRNA
levels compared to the empty vector controls (p < 0.05). Protein expression of PPARg was
significantly increased with CYP2J2 overexpression (p < 0.01), but there were no changes in
PGC-1a or UCP1 protein levels compared to the empty vector controls. There were no
significant alterations observed between the CYP2J2 overexpressing cells receiving doxycycline
or water, suggesting that increasing CYP2J2 expression beyond the extent observed in the cells
treated with water may not be sufficient to confer further changes in gene and protein expression,
at least in the markers that were tested. These data suggest that overexpression of CYP2J2 may
not be sufficient to affect human brown adipocyte differentiation.

4.2. Discussion
BAT has recently emerged as a novel target for treatment of obesity and its related
metabolic disorders. Accumulating evidence suggests that CYP epoxygenase overexpression
may confer benefits for metabolic disease, presumably due to increased EpFA bioavailability,
but it is unknown if CYP epoxygenase overexpression directly affects brown adipogenesis and
whether the beneficial effects of CYP epoxygenase overexpression in metabolic diseases are
partially mediated through enhanced BAT development and activation. Increasing EpFA
concentrations in white adipocytes has been shown to inhibit white adipocyte differentiation [14,
82], suggesting these epoxygenase enzymes may play a regulatory role in adipogenesis.
However, to our knowledge, adipocyte-specific expression of CYP epoxygenases has not been

38

extensively analyzed, and no studies on CYP epoxygenase expression and brown adipocyte
differentiation have been reported.
This study is the first to report CYP epoxygenase expression patterns throughout the
course of adipocyte differentiation. We show that similar CYP isoforms (Cyp2j6, Cyp2j9,
Cyp2j13, Cyp2c44, Cyp2c65, Cyp2c66) are the most highly expressed in both murine brown and
white adipocytes, suggesting that these isoforms are the key drivers of murine adipocyte EpFA
production. Furthermore, we show that CYP epoxygenase expression is higher in mature
adipocytes vs. preadipocytes, except in the most strongly differentiated murine brown
adipocytes, suggestive of a bell-shaped pattern in relation to adipocyte differentiation and
epoxygenase expression levels. A previous study showed that Cyp2j9 and Cyp2c55 expression
slightly decreased in mature white adipocytes compared to the preadipocytes [14]. It is possible
that degrees of white adipocyte differentiation may be different between our model and the
published study. Further studies are needed to confirm the expression patterns of Cyp2j and 2c
isoforms in murine brown and white adipogenesis.
We also demonstrated that Cyp2j mRNA levels showed an upward trend in the iBAT of
HFD-fed mice. Given that obesity is associated with reduced BAT mass and activity [22], this
finding seems to suggest that elevated Cyp2j expression is also associated with reduced BAT
mass and activity, which seemingly aligns with our finding that Cyp2j mRNA levels were
suppressed in more strongly differentiated brown adipocytes. Together, this implicates that
Cyp2j may be a negative regulator for brown adipocyte development. This suspected impact of
Cyp2j expression on brown adipogenesis was further validated by our studies of Cyp2j13
overexpression and knockdown, which significantly suppressed and promoted brown adipocyte
differentiation, respectively. Previous studies have shown that Cyp2j13 is highly expressed in
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mouse kidneys and hearts, but not detectable in the liver [64, 131, 132]. Overall, however, this
epoxygenase isoform is largely unexplored, and we are the first to closely examine its expression
in adipose tissue. Our data strongly indicates that Cyp2j13 in adipose tissue plays a critical role
in brown adipogenesis and may be a novel target for obesity treatment and prevention.
Sustained white adipogenesis is integral in the initiation and progression of obesity and
its related diseases. EET analogs have been shown in multiple studies to suppress white
adipocyte differentiation [14, 82, 86], and knockout of the major rat epoxygenase Cyp2j4 in
MSCs resulted in spontaneous adipogenesis, in that the MSCs became mature adipocytes without
the addition of adipogenic media [87]. These data indicate that EpFAs inhibit white
adipogenesis; however, it has been speculated that these lipid mediators elicit opposing effects
on brown adipogenesis. We have demonstrated that sEH inhibition by t-TUCB dose-dependently
promotes brown adipogenesis in vitro [112]. Another study utilizing a different sEH inhibitor
also reported enhanced iBAT mass in fat-1 mice which express an n-3 desaturase that elevates
endogenous n-3 PUFAs [107]. It has been suggested that this enhanced brown differentiation
was a result of EpFA stabilization by sEH inhibition. However, results of the current study
suggest that perhaps the promotion of brown adipogenesis by t-TUCB and other sEH inhibitors
may be primarily attributed to their off-target effects, and not simply the inhibition of the EpFAdegrading enzyme. It is worth noting that in our previous study, t-TUCB was also shown to
activate both PPARg and PPARa in the brown preadipocytes in vitro [112], so it cannot be ruled
out that the promotion of cellular brown adipogenesis by t-TUCB was a direct result of its
activation of the PPARs and their downstream target genes, and not due to EpFA actions.
Cyp2j13 epoxygenase overexpression presumably elevates EpFAs, implicating a similar
suppressive effect of these lipid mediators on both brown and white adipogenesis. A comparable
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influence of EpFAs on differentiation of both adipocyte types is certainly possible, considering
that both brown and white adipocyte differentiation are under the master regulation of PPARg,
and both cell types express similar CYP epoxygenase isoforms and exhibit an upregulation of
sEH expression throughout differentiation [81, 112]. However, a limitation in our current study
is that we did not measure the effect of Cyp2j13 expression on EpFAs, so we cannot definitively
state that the observed suppression of brown adipogenesis is attributed to enhanced EpFAs.
Studies directly examining the effect of EpFAs and stable analogs on cellular brown
adipogenesis are warranted to further elucidate the role of the CYP epoxygenase pathway in
brown adipocyte development and activation.
It is also important to mention that it is unknown if differing EpFAs may elicit
contrasting effects on brown adipocytes, which may impact the observed effects of CYP
overexpression, since we are unsure of how the EpFA profile of the cells were affected in our
studies. There are some discrepancies in functions between the n-6-derived EETs and the n-3
varieties. For example, EETs are recognized as more proliferative and angiogenic, while EEQs
and EDPs exert opposing actions [67]. There is substantial evidence proposing a role of fish oil
in the promotion of brown adipogenesis [114-121], and it has been speculated that many of the
suggested benefits of fish oil in cardiovascular disease and other conditions may actually be
attributed to their epoxide derivatives [123]. Perhaps, addition of EPA or DHA as substrates in
conjunction with CYP overexpression may produce opposite effects on brown differentiation
than what was observed in our study.
Ultimately, the exact mechanism through which Cyp2j13 overexpression inhibits brown
adipogenesis remains to be determined. It is likely this suppression occurs through a similar
manner in which EETs inhibit white adipogenesis as shown in other studies. A previous study
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postulated that EETs elicit anti-adipogenic effects by specifically targeting signaling events in
the early phase of adipogenesis, as administration of EET analogs solely in the later phases
diminished the suppressive effect [14]. In the early phases of preadipocyte differentiation,
inhibition of the ERK signaling pathway and activation of the cAMP/PKA and AMPK signaling
pathways have been shown to inhibit differentiation of 3T3-L1 cells with repression of PPARg,
C/EBPa, and SREBP1c activation [133-135]. Increased EETs through epoxygenase
overexpression or administration of stable analogs has been shown to inhibit ERK
dephosphorylation in endothelial cells, activate AMPK in the liver, skeletal muscle, aorta, and
kidney, and activate the cAMP/PKA pathway in the vasculature [15, 82, 94, 136, 137]. Thus, we
can hypothesize that CYP-derived EETs and other EpFAs are involved in complex interactions
with a variety of signaling pathways that ultimately suppress adipogenic transcription factor
networks, particularly in the early phases of brown adipogenesis.
There is also question as to whether all Cyp2j isoforms possess the ability to inhibit
brown differentiation, or if this is unique to certain isoforms, such as Cyp2j13. A previous study
analyzed expression of all murine Cyp2j and Cyp2c isoforms in the liver, duodenum, kidney, and
brain in response to LPS-induced inflammation, and reported that changes in mRNA expression
levels were both isoform- and tissue-specific [132]. This strengthens the idea that although each
of the Cyp2j and Cyp2c isoforms likely possess epoxygenase ability, their overall effect on
cellular physiological processes may differ between isoforms and tissues. It would be beneficial
to examine overexpression and knockdown of other CYP isoforms in brown adipocytes in order
to compare effects on differentiation potential. Cyp2j6 may be an interesting candidate to
explore, as it is the most abundant murine Cyp2j isoform in adipose tissue based on our data and
the official homolog to human CYP2J2 [138]. Of the Cyp2c genes, analysis of Cyp2c44
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overexpression could be noteworthy based on its unique expression patterns compared to the
other Cyp2c isoforms, suggesting it may play a distinctive role in cellular processes.
CYP2J2 overexpression did not significantly affect human brown adipocyte
differentiation based on the markers analyzed. However, it is possible that CYP2J2
overexpression produced effects on target genes that were not examined in the current study,
such as those involved in inflammation and oxidative stress. CYP2J2 overexpression has been
shown to attenuate HFD-and aging-induced increases in body weight, adiposity, serum lipids,
insulin resistance, and vascular dysfunction [89, 92, 93, 94, 96]. Primary mechanisms reported
for these outcomes include activation of PPARg, AMPK, and PI3K/Akt pathways, resulting in
reduced inflammation, increased glucose uptake, and enhanced lipid metabolism. Endothelialspecific CYP2J2 overexpression has been shown to improve dyslipidemia through activation of
AMPK and elevation of PPARa expression [94]. In our study, however, there were no
significant changes in PPARa mRNA expression with CYP2J2 overexpression in the human
brown cells. Perhaps, this can be attributed to the lack of metabolic stress, as alterations in
markers of lipid metabolism were only present in the CYP2J2 overexpressing mice when fed a
HFD [94]. In fact, many of the beneficial metabolic effects of CYP2J2 overexpression previously
reported are only apparent when subjects are placed under metabolic stress such as a HFD or
aging, with no differences observed in the basal state. Much like white adipocytes, brown
adipocytes are also capable of producing pro-inflammatory cytokines under circumstances of
metabolic stress, and accumulating evidence suggests that inflammation can directly alter BAT
development and thermogenic activity [139, 140]. We have previously shown that activation of
Toll-like receptor (TLR)4, TLR2, or nucleotide-oligomerization domain-containing protein
(NOD)1 in brown adipocytes induces inflammation and impairs UCP1 expression and
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mitochondrial respiration [129]. Although CYP2J2 overexpression did not remarkably affect the
expression of brown marker genes in the basal state, it would be intriguing to examine if CYP2J2
overexpression may help alleviate inflammation-induced suppression of brown adipocyte
differentiation and activity.
It is also important to discuss the complex interactions of CYP epoxygenases and
PPARg expression. Despite reported suppressive effects of EETs on white adipogenesis, their
involvement in this process is not straightforward and some findings are contradictory to this
notion. EETs have been shown to bind and activate PPARg, the master regulator of both brown
and white adipocyte differentiation [77]. PPARs heterodimerize with RXR and bind to PPREs in
target genes, such as UCP1 in brown adipocytes, in order to regulate their expression [33].
Rosiglitazone, a synthetic ligand for PPARg, has been shown to enhance brown adipocyte
differentiation [141]. Although EETs have demonstrated to be PPARg ligands, data regarding the
effect of EETs and CYPs on PPARg expression are still unclear. EETs have been shown to
repress PPARg expression in white adipocyte differentiation [14, 82, 93]. However, another
study demonstrated that EET analogs in the presence of an sEH inhibitor activated PPARg and
increased Fabp4 mRNA expression in 3T3-L1 preadipocytes, a general marker of adipocyte
differentiation [77], suggesting the effects of EETs on white adipogenesis are not straightforward
and may depend on the cellular conditions and interactions with other signaling pathways. In our
current study, Cyp2j13 overexpression significantly suppressed PPARg mRNA and protein
expression in the differentiated murine brown adipocytes. However, knockdown of this gene also
resulted in significant reduction of Pparg mRNA expression, and protein levels were not
affected. Conversely, CYP2J2 overexpression did not affect PPARg mRNA levels, but
significantly increased its protein expression. These findings highlight the complex nature of
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CYP epoxygenase interaction with PPARg expression and indicate that the effect of CYPs on
PPARg expression levels may be variable depending on the tissue microenvironment. Further
studies are needed to define the effects of the CYP epoxygenase pathway on PPARg expression
in different adipose tissue depots and under circumstances of metabolic stress.
In conclusion, the results presented in the current study help to characterize CYP
epoxygenase expression in adipocytes and suggest that Cyp2j13 is a critical epoxygenase
involved in the regulation of murine brown adipogenesis. Our findings indicate that EETs and
other EpFAs may suppress brown adipogenesis through a similar manner in which these lipid
mediators suppress white adipogenesis. Although CYP2J2 overexpression did not remarkably
affect the expression of brown marker genes in the basal state, further studies are warranted to
examine if CYP2J2 overexpression may help alleviate inflammation-induced suppression of
brown adipocyte differentiation and activity. Moreover, the roles of CYP2J2 should be further
investigated by gene knockdown and pharmacological antagonism. Additional studies analyzing
other CYP epoxygenase isoform overexpression and knockdown are necessary to generate a
complete picture on the role of CYP epoxygenases in brown adipogenesis.
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Figure 1. CYP epoxygenase expression in murine brown adipocyte differentiation
Murine brown preadipocytes were induced to differentiate for 6 days. Total RNA samples were
collected on day 0, day 2, day 4, and day 6. Upon initiation of differentiation, select cells
received induction media for 24 hours (indicated as the day collected + I) to induce a stronger
degree of differentiation. mRNA expression was quantified relative to the loading control 36b4
and is displayed as fold of the day 0 samples (A, B, C). (A) Relative mRNA expression of
brown adipocyte marker genes Ucp1, Pgc-1a, Pparg, Prdm16, and Cidea. (B) Relative mRNA
expression of Cyp2j epoxygenase genes Cyp2j6, Cyp2j8, Cyp2j9, and Cyp2j13. (C) Relative
mRNA expression of Cyp2c epoxygenase genes Cyp2c37, Cyp2c44, Cyp2c50, Cyp2c55,
Cyp2c65, and Cyp2c66. (D) Total mRNA abundance of Cyp2j and Cyp2c genes on day 0 and
day 6 of differentiation, relative to 36b4. Data = Mean ± SEM (n=3). *, **, ***, p < 0.05, p <
0.01, and p < 0.001, respectively, differentiation only groups compared to day 0 and induction
groups compared to day 0 (A, B, C) or between sample groups (D).
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Figure 2. CYP epoxygenase expression in 3T3-L1 adipocyte differentiation
3T3-L1 preadipocytes were induced to differentiate for 7 days. Total RNA samples were
collected before each media change on day 0, day 3, day 5, and day 7. mRNA expression was
quantified relative to the loading control 36b4 and is displayed as fold of the day 0 samples (A,
B, C). (A) Relative mRNA expression of adipocyte differentiation marker genes Fabp4, Fasn,
Pparg, C/ebpa, and Scd1. (B) Relative mRNA expression of Cyp2j epoxygenase genes Cyp2j6,
Cyp2j8, Cyp2j9, and Cyp2j13. (C) Relative mRNA expression of Cyp2c epoxygenase genes
Cyp2c37, Cyp2c44, Cyp2c50, Cyp2c55, Cyp2c65, and Cyp2c66. (D) Total mRNA abundance of
Cyp2j and Cyp2c genes on day 0 and day 7 of differentiation, relative to 36b4. Data = Mean ±
SEM (n=3). *, **, ***, p < 0.05, p < 0.01, and p < 0.001, respectively, compared to the day 0
sample.
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Figure 3. CYP epoxygenase expression in human brown adipocyte differentiation
Human brown preadipocytes were induced to differentiate for four weeks. Total RNA samples
were collected on day 0, week 1, week 2, week 3, and week 4 of differentiation. mRNA
expression was quantified relative to the loading control 36B4 and is displayed as fold of the day
0 samples (A, B). (A) Relative mRNA expression of brown adipocyte marker genes UCP1,
PGC-1a, and PPARg. (B) Relative mRNA expression of human CYP epoxygenase genes
CYP2J2, CYP2C8, CYP2C9, CYP2C18, and CYP2C19. (C) Total mRNA abundance of CYP
epoxygenase genes on day 0 and week 4 of differentiation, relative to 36B4. Data = Mean ± SEM
(n=3). *, **, ***, p < 0.05, p < 0.01, and p < 0.001, respectively, compared to the day 0 sample.
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Figure 4. CYP epoxygenase expression in diet-induced obesity
Six-week old C57BL/6J mice were fed with either a high-fat diet (60% kcal from fat) or a
regular chow diet for 20 weeks, before being sacrificed at 26 weeks of age. iBAT, eWAT, and
iWAT were collected and total RNA was isolated. mRNA expression was quantified relative to
the loading control 36b4 and is displayed as fold of the regular chow fed controls. (A) Relative
mRNA expression of Cyp2j genes in iBAT (n=7). (B) Relative mRNA expression of Cyp2c
genes in iBAT (n=7). (C) Relative mRNA expression of Cyp2j genes in eWAT (n=6). (D)
Relative mRNA expression of Cyp2c genes in eWAT (n=6). (E) Relative mRNA expression of
Cyp2j genes in iWAT (n=6). (F) Relative mRNA expression of Cyp2c genes in iWAT (n=6).
Data = Mean ± SEM. *, **, ***, p < 0.05, p < 0.01, and p < 0.001, respectively, compared to the
regular chow fed controls.
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Figure 5. Cyp2j13 overexpression suppresses murine brown adipocyte differentiation
Murine brown preadipocytes were stably transfected with the Myc-DDK-tagged Cyp2j13
expression plasmid or the empty vector (pCMV6). Stably transfected cells were selected for two
weeks with neomycin. Individual clones were selected and expanded to assess differentiation
potential. Cells were stained and total RNA and protein samples were collected on day 6 of
differentiation for analysis. mRNA expression was quantified relative to the loading control
36b4. Densitometry of protein bands were normalized to the loading control ERK1/2 or nonspecific bands. Data are displayed as fold of the empty vector controls. (A) Protein bands and
densitometry for Myc-tagged CYP2J13 in the murine brown preadipocytes (n=1). (B) ORO
stained cell morphology and ORO absorbance for the differentiated adipocytes (n=3). (C)
Relative mRNA expression of Cyp2j13, Ucp1, Pgc-1a, Cidea, Pparg, Fabp4, Fasn, and
Ppara in the differentiated adipocytes (n=6). (D) Protein bands and densitometry for UCP1,
PGC-1a, PPARg and ERK1/2 in the differentiated adipocytes (n=3). Data = Mean ± SEM. *, **,
***, p < 0.05, p < 0.01, and p < 0.001, respectively, compared to the empty vector controls.
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Figure 6. Cyp2j13 knockdown enhances murine brown adipocyte differentiation
Murine brown preadipocytes were transduced with lentiviral particles against Cyp2j13 or a
scrambled non-targeting control. Stably infected cells were selected for two weeks with
neomycin. Individual clones were selected and expanded to assess differentiation potential. Total
RNA and protein samples were collected on day 6 of differentiation for analysis. mRNA
expression was quantified relative to the loading control 36b4. Densitometry of protein bands
were normalized to the loading control ERK1/2. Data are displayed as fold of the non-targeting
controls. (A) Relative Cyp2j13 mRNA expression in the murine brown preadipocytes. (B)
Relative mRNA expression of Ucp1, Pgc-1a, Cidea, Pparg, Fabp4, Fasn, and Ppara in the
differentiated adipocytes. (C) Protein bands and densitometry for UCP1, PGC-1a, PPARg, and
ERK1/2 in the differentiated adipocytes. Data = Mean ± SEM (n=3). *, **, ***, p < 0.05, p <
0.01, and p < 0.001, respectively, compared to the controls.
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Figure 7. CYP2J2 overexpression does not affect human brown adipocyte differentiation
Human brown preadipocytes were transfected with the CYP2J2 expression plasmid or the empty
vector (pSBtet). Stably transfected cells were selected for two weeks with puromycin. At 48
hours prior to confluency and at every media change thereafter, cells received either 1 µg/ml
doxycycline to induce stronger expression of CYP2J2, or the vehicle control (water). Total RNA
and protein samples were collected on week 3 of differentiation for analysis. mRNA expression
was quantified relative to the loading control 36B4. Densitometry of protein bands was
normalized to the loading control ERK1/2. Data are displayed as fold of the empty vector
controls without doxycycline. (A) Validation of CYP2J2 overexpression in human brown
preadipocytes after 48 hours treatment with doxycycline or water. (B) Relative mRNA
expression of CYP2J2, UCP1, PGC-1a, PPARg, FABP4, FASN, and PPARa in the differentiated
human brown adipocytes (C) Protein bands for UCP1, PGC-1a, PPARg, CYP2J2 and ERK1/2 in
the differentiated human brown adipocytes. Densitometry for UCP1, PGC-1a, and PPARg is
shown. Data = Mean ± SEM (n=3). *, **, ***, p < 0.05, p < 0.01, and p < 0.001, respectively,
compared to the empty vector controls without doxycycline.
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